Skip to main content
. 2013 Feb 21;52(8):1593–1601. doi: 10.3109/0284186X.2013.770164

Figure 3.

Figure 3.

Differences between counties in use of intravenous docetaxel chemotherapy treatment, i.e percentage of men dying from prostate cancer who received intravenous docetaxel chemotherapy prior to death. Data from Skåne county is missing (gray).